Stockreport

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer

Tyme Technologies, Inc.  (TYME) 
Last tyme technologies, inc. earnings: 2/5 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: tymeinc.com/investors
PDF 68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5. [Read more]